WuXi AppTec to shutter Texas-based clinical research business news2025-10-29T10:31:41+00:00October 29th, 2025|Endpoints News|
DNA-chopping enzyme that breaks up NETs may offer new way to fight autoimmune disease, early data from Neutrolis suggestnews2025-10-29T10:00:58+00:00October 29th, 2025|Endpoints News|
Lilly keeps up legal fight against GLP-1 compounders news2025-10-28T19:40:58+00:00October 28th, 2025|Endpoints News|
FDA clears at-home use for Delix’s next neuroplastogen studynews2025-10-28T19:22:46+00:00October 28th, 2025|Endpoints News|
Everlywell’s at-home testing business evolutionnews2025-10-28T18:53:09+00:00October 28th, 2025|Endpoints News|
FDA’s biosimilars director says agency seeks to ‘streamline’ developmentnews2025-10-28T18:41:12+00:00October 28th, 2025|Endpoints News|
Eli Lilly, Nvidia say they’ll build pharma’s most powerful supercomputernews2025-10-28T18:30:18+00:00October 28th, 2025|Endpoints News|
Genesis Molecular AI claims its model Pearl beats AlphaFold 3news2025-10-28T18:30:15+00:00October 28th, 2025|Endpoints News|
More than a third of Lilly’s new Zepbound prescriptions are coming from DTCnews2025-10-28T16:28:14+00:00October 28th, 2025|Endpoints News|
BioMarin looks to divest hemophilia gene therapy Roctaviannews2025-10-28T15:29:37+00:00October 28th, 2025|Endpoints News|
